Test of LED System that Warns Drivers of Black Ice Under Way in Susono, Japan
2.3.2023 15:32:00 EET | Business Wire | Press release
Susono City, Stanley Electric Co., Ltd., Kaga FEI Co., Ltd., NTT Communications Corporation and Dassault Systèmes K.K.. announced jointly today that a system for warning drivers about transparent ("black") ice using a smart streetlight developed by the four companies is being tested on a public road in Susono, Japan from February 10 to March 31. The test will verify the effectiveness of the system in preventing car slippage and pedestrian falls in a public area of Susono.
For the test, a smart streetlight that projects an illuminated warning ("Caution Ice") on the road surface was installed on a light pole in front of Yanagibata Bridge in Ishiwaki, Susono City. During the test, data from an edge AI camera and sensors mounted on the smart streetlight are being collected and transmitted via mobile communication to a center for analysis, including by comparing the number of ice-related accidents at the site before and after the test. Also, residents will be surveyed to see if their awareness of ice-related hazards is changed by the operation of the system.
The roles of each company are as follow:
Stanley Electric:
- Develop, manufacture and supply LED streetlight and illumination-projection equipment
Kaga FEI:
- Provide edge AI camera and sensors
- Develop embedded AI system
NTT Communications:
- Implement mobile communications (IoT Connect Mobile® TypeS1)
- Provide platform for visualizing and storing collected data (Things Cloud®2)
Dassault Systèmes:
- Provide virtual twin3 platform (3DEXPERIENCE© platform)
- Build virtual twins, data visualization, and scenario analysis based on system and terrain data
Once the system is demonstrated to be fully reliable and effective, its broad deployment in other municipalities will be promoted along with the use of smart streetlights in emerging countries where road lighting is uncommon. In addition, by combining data from the system with weather data, etc., it will be possible to provide enhanced weather-related driving information, such as traffic congestion forecasts in areas where snow is expected, keeping drivers better informed while also supporting the work of road and traffic managers.
NTT Com's KOEL4 design studio will join the project to help research opportunities for commercial applications. It is expected that the system could be applied in business areas such as shopping malls and other commercial facilities as well as Park-PFI, a publicly solicited, privately financed initiative for the maintenance and management of urban parks in Japan.
Susono, which has adopted the slogan "Japan's most citizen-oriented city hall," is actively modernizing its urban areas through the introduction of universal-design pedestrian spaces, advanced technology and data analysis, aiming to realize zero fatalities and less than 200 injuries due to accidents per year by 2025.
1 IoT Connect Mobile® TypeS is an eSIM-based mobile data communication service.
2 Things Cloud® is an IoT platform that packages data collection, visualization, analysis and management functions via connected sensors and devices tailored to specific business environments.
3 Virtual twin, more than a digital copy of the real world, is a representation of the real world based on mathematical models and scientific principles.
4 The KOEL design studio was established in April 2020 within NTT Com's Innovation Center, which is dedicated to the creation of new businesses.
About Stanley Electric
Stanley Electric Co., Ltd. was founded in 1920 to manufacture and sell automotive light bulbs and other specialty light bulbs. Today, the company is highly regarded worldwide for products it supplies to major automobile manufacturers. Starting with the world's first commercial high-brightness LEDs in 1976, the company has developed numerous components and other electronic that contribute to safety and energy conservation, including smart streetlights. Please visit https://www.stanley.co.jp/
About Kaga FEI
Kaga FEI Co., Ltd. is an electronics trading company that sells consumer and industrial electronic devices and products for automobiles, AV equipment, communications equipment and information processing equipment. The company and its global partners also provide technical support and solution services that combine commercial products and technologies, including electronics manufacturing services, in markets worldwide. Please visit https://www.kagafei.com/jp/
About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating 'virtual twin experiences’ of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production.
Dassault Systèmes’ 20,000 employees are bringing value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit https://www.3ds.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301006236/en/
Contact information
For more information
Susono
Business: Strategic Promotion Division
+81-55-995-1804; kikaku@city.susono.shizuoka.jp
Road management: Construction Management Division
+81-55-995-1855; kanri@city.susono.shizuoka.jp
Stanley Electric
Yokohama Technical Center, Lighting Application Division
+81-45-910-6629
Kaga FEI
Partner Business Promotion Department
System Business Center, Solutions Division
ml-snk_colbiz_pj@jp.kagafei.com
NTT Communications
Business Solution Division, Business Solution Department
bbx-5bs3g@ntt.com
Dassault Systèmes
Marketing Representative, Public Relations Division
+81-3-4321-3506; japan.marketing@3ds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
